Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesChildhood acute myeloid leukaemiaProgress in acute myeloid leukemiaAn overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentFLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.'Acute myeloid leukemia: a comprehensive review and 2016 update'FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsERG transcriptional networks in primary acute leukemia cells implicate a role for ERG in deregulated kinase signalingLigand-target prediction by structural network biology using nAnnoLyzeFuture prospects of therapeutic clinical trials in acute myeloid leukemia.A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDThe Cytokine Flt3-Ligand in Normal and Malignant HematopoiesisFLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemiaPrimary refractory acute myeloid leukaemia - in search of better definitions and therapies.Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemiaPatterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaPhysiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaPhase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaShortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometryThe Biology and Targeting of FLT3 in Pediatric Leukemia.Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticlesFLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasmThe Future of Targeting FLT3 Activation in AML.FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitorsPhase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.Treatment of FLT3-ITD acute myeloid leukemia.Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoFLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotypePim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication
P2860
Q26752940-91ABC261-EA9A-409A-A85E-5A31EB4D230DQ27005960-D9F67E45-D272-485C-887F-BEBE2B346EA5Q27024006-6D6FF936-5ABF-45F8-A41C-4279CA59FA19Q27027207-A56BC1F3-77C1-4CC3-A211-23F615F1A9FDQ27028163-F2C6F63C-4D4C-4812-963E-B2D054B86629Q27851694-5C65D1D9-5655-41A2-B91C-D0FA2F6102BDQ28072539-6FAC6D4E-0538-4F92-8E31-B57DDCDD0281Q28289859-B961F6EA-DE99-43A9-BB2F-3ADFB13916E9Q28484833-8C75A2D1-FD1A-4BD2-823B-244FAEA02A84Q28545126-99224CA8-09E6-4597-A66A-367FABB41F58Q30244168-2562A589-7ADA-49AE-8B8F-F5BC92F82988Q33403207-4DC1D2A8-21A7-412E-9A56-86A6DC1F6B50Q33437992-4923EDC5-496D-430B-AF99-99F8A8121D90Q33698015-46C4528F-399C-47A7-9165-3F3C9AB90B75Q33710062-D0BEA7BF-2DBC-4712-A0A2-064FDFA75F9DQ33749036-5ECBFEA8-31B9-4EFB-AEE2-95D463D7D5E4Q33767026-0EA1F752-6BB0-4628-8413-2E81ACC2E3B2Q33798909-40B134B2-333A-4AD9-875E-8B64A8330EB1Q33838356-03108EE7-ED9B-4192-AEDB-2138A28F552DQ33856839-D355599D-9EE5-40AE-9B19-AA38153E13D9Q33877213-58795902-1E55-42BD-9B7E-586F54694118Q33880828-201413E8-24FA-4B22-837B-A45781A77012Q33913329-5CFA19FB-21D0-4B1A-9851-2A97BE89B6A0Q33929912-1BD5A22B-C723-47D6-BAE7-628271F2670CQ33943277-00767641-E0F3-4E8A-B813-C61BD6CD2B82Q33986236-270328EB-0784-483A-9B34-B5294DA1C9E2Q34004131-3324BF02-8235-41E5-9463-12DF93C94A2EQ34193514-42366119-F05C-40D1-BAB4-9644AF4104E2Q34209373-BC1EA2EC-B106-4A3B-8168-0B5DED3CBEDDQ34229555-2A241397-B2B3-4142-8A8C-6F886935A9DEQ34334066-5389614C-56CE-4E50-9851-7A455AD18673Q34408941-908FA091-69B2-4302-82B5-3935C7317019Q34555386-F03AA799-B852-4061-96B6-C45D54F1D33FQ34566158-EC101673-401A-4EF4-B7EE-C367CE191FFAQ34620695-B1AC3C27-47C2-4197-999E-F7BA594C2FF8Q34636735-52C0B7D6-E35B-4042-938F-294A6CC94691Q34709391-0A7CA261-44EC-4779-981F-7CB4BCB72960Q34754329-421793A6-3965-4E28-B048-B4E6F05591D6Q34890418-A1B29FF9-AF48-4EAF-9FD9-D967081E7ADEQ34990221-D47955D8-ACB7-40B8-BA42-F3BE3C95A761
P2860
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase I/II study of combinatio ...... s with acute myeloid leukemia.
@ast
Phase I/II study of combinatio ...... s with acute myeloid leukemia.
@en
Phase I/II study of combinatio ...... s with acute myeloid leukemia.
@nl
type
label
Phase I/II study of combinatio ...... s with acute myeloid leukemia.
@ast
Phase I/II study of combinatio ...... s with acute myeloid leukemia.
@en
Phase I/II study of combinatio ...... s with acute myeloid leukemia.
@nl
prefLabel
Phase I/II study of combinatio ...... s with acute myeloid leukemia.
@ast
Phase I/II study of combinatio ...... s with acute myeloid leukemia.
@en
Phase I/II study of combinatio ...... s with acute myeloid leukemia.
@nl
P2093
P2860
P50
P356
P1476
Phase I/II study of combinatio ...... s with acute myeloid leukemia.
@en
P2093
B Nebiyou Bekele
Daniel Jones
Deborah Thomas
Keith Pratz
Marina Y Konopleva
Mark Brandt
Mark Levis
Rajyalakshmi Luthra
Sherry R Pierce
P2860
P304
P356
10.1200/JCO.2009.25.4888
P407
P50
P577
2010-03-08T00:00:00Z